Solid pseudopapillary neoplasm (SPN) of the pancreas is a low-grade malignant tumor primarily treated with surgical resection. However, the oncologic safety of parenchyma-sparing resection (PSR) and the necessity of lymphadenectomy remain debated. This prospective cohort study evaluates these aspects based on long-term outcomes.
Solid pseudopapillary neoplasm (SPN) is a rare pancreatic tumor, accounting for approximately 1-3% of all pancreatic neoplasms, and predominantly affects young women . Although historically classified as a borderline lesion, SPN is currently regarded as a low-grade malignant neoplasm with an excellent long-term prognosis, with complete surgical resection achieving cure in 85-95% of patients. Even in the presence of recurrence or limited distant metastasis, aggressive surgical management can still result in prolonged survival. Given this indolent biological behavior and long life expectancy, the primary surgical challenge in SPN has gradually shifted from achieving oncologic radicality alone to balancing oncologic safety with long-term functional preservation. Parenchyma-sparing resection (PSR) has therefore gained increasing attention in the management of SPN. By preserving pancreatic parenchyma and avoiding complex gastrointestinal reconstruction, PSR has the potential to reduce surgical trauma and preserve long-term endocrine and exocrine function. However, concerns persist regarding its oncologic adequacy, particularly the risk of positive resection margins, limited lymph node assessment, and postoperative morbidity. Current evidence supporting PSR in SPN remains largely derived from small retrospective series, and robust data addressing long-term oncologic outcomes and functional consequences are lacking. Owing to the rarity and low malignant potential of SPN, prospective randomized trials comparing PSR with conventional oncologic resection (OR) are unlikely to be feasible. Consequently, optimal surgical strategy for SPN remains controversial. Using a large, prospectively maintained database, this study aimed to compare PSR and OR with respect to long-term oncologic outcomes, perioperative safety, and postoperative functional preservation. In addition, given the extremely low incidence of lymph node metastasis in SPN, we sought to further evaluate the necessity of routine lymph node dissection from a long-term outcome perspective.
Study Type
OBSERVATIONAL
Enrollment
708
PSR included enucleation (EN), duodenum-preserving pancreatic head resection (DPPHR), central pancreatectomy (CP), and spleen-preserving distal pancreatectomy (SPDP). OR included pancreatoduodenectomy (PD), distal pancreatectomy with splenectomy (DPS), and total pancreatectomy (TP).
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Reoperation rate
Reoperation rate within 90 days after surgery.
Time frame: Within 90 days after surgery.
Rate of pancreatic enzyme-dependent malabsorption
Postoperative pancreatic enzyme-dependent malabsorption rate.
Time frame: Through study completion, an average of 3 year.
Rate of new-onset diabetes
Postoperative new-onset diabetes rate.
Time frame: Through study completion, an average of 3 year.
R0 resection rate
R0 margin rate on postoperative pathological assessment.
Time frame: From the date of surgery to 1 month after surgery.
Recurrence-free survival (RFS)
The time of surgery to the time of tumor recurrence or death.
Time frame: Through study completion, an average of 3 year.
Incidence of Clinically Relevant Postoperative Pancreatic Fistula
Clinically Relevant Pancreatic Fistula including Grade B fistulas, which require treatment beyond simple drainage, as well as Grade C fistulas.
Time frame: Within 90 days after surgery.
Perioperative complication rate according to the Clavien-Dindo classification
Adverse events that occur during or after the surgery, reported according to the Clavien-Dindo classification.
Time frame: Within 90 days after surgery.
Postoperative pancreatic hemorrhage (PPH) rate
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Postoperative pancreatic hemorrhage (PPH) rate within 90 days after surgery, reported according to the ISGPS definition.
Time frame: Within 90 days after surgery.
Delayed gastric emptying (DGE) rate
Delayed gastric emptying (DGE) rate within 90 days after surgery, reported according to the ISGPS definition.
Time frame: Within 90 days after surgery.